Multiplexed magnetic nanoparticle-antibody conjugates (MNPs-ABS) based prognostic detection of ovarian cancer biomarkers, CA-125, β-2M and ApoA1 using fluorescence spectroscopy with comparison of surface plasmon resonance (SPR) analysis

• Published in: Biosensors & bioelectronics Vol. 73; pp. 146 - 152
• Main Authors: Pal, Manoj K., Rashid, Mohammad, Bisht, Manisha
• Format: Journal Article
• Language: English
• Published: England Elsevier B.V 15.11.2015
• Subjects: Adult; Antibodies; Antibodies, Immobilized; Apolipoprotein A-I - blood; beta 2-Microglobulin - blood; Biomarkers, Tumor - blood; Biosensor; CA-125 Antigen - blood; Case-Control Studies; Early Detection of Cancer - methods; Female; Functionalized MNPs; Humans; Limit of Detection; Magnetite Nanoparticles; Membrane Proteins - blood; Middle Aged; Multiplexed; Nanoconjugates; Ovarian cancer; Ovarian Neoplasms - blood; Ovarian Neoplasms - diagnosis; Prognosis; Spectrometry, Fluorescence - methods; Surface Plasmon Resonance - methods; Antibodies; Biosensor; Functionalized MNPs; Multiplexed; Ovarian cancer
• ISSN: 0956-5663; 1873-4235
• DOI: 10.1016/j.bios.2015.05.051

A multiplexed MNPs-Abs based fluorescence spectroscopic system in analysis of serum biomarkers; CA-125, β2-M and ApoA1 for the early detection of ovarian cancer was first time proposed. The lowest detection limits measured in multiplexed setup were 0.26U/mL, 0.55ng/mL and 7.7ng/mL respectively for CA-125, β2-M and ApoA1. A comparative real sample analysis of healthy normal (Control), benign and ovarian cancer patients with SPR has also been done to validate the process. Moreover CA-125 detection only confirms 50–60% of early stage disease. This multiplexed system achieved sensitivity and specificity up to 94% and 98% respectively to distinguish early stage ovarian cancer patients from healthy individuals. •A fluorescence spectroscopic based magnetic nanoparticle-antibody conjugates (MNPs-Abs) system for the prognostic detection of ovarian cancer biomarkers, CA-125, β-2M and ApoA1 has been developed.•Comparative SPR analysis of CA-125, β-2M and ApoA1.•Detection multiplexing of ovarian cancers biomarkers; CA-125, β-2M and ApoA1.